CA2478342A1 - Heterocyclic amide derivatives for the treatment of diabetes and other diseases - Google Patents

Heterocyclic amide derivatives for the treatment of diabetes and other diseases Download PDF

Info

Publication number
CA2478342A1
CA2478342A1 CA002478342A CA2478342A CA2478342A1 CA 2478342 A1 CA2478342 A1 CA 2478342A1 CA 002478342 A CA002478342 A CA 002478342A CA 2478342 A CA2478342 A CA 2478342A CA 2478342 A1 CA2478342 A1 CA 2478342A1
Authority
CA
Canada
Prior art keywords
compound
carbon atoms
oxo
compounds
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478342A
Other languages
English (en)
French (fr)
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A. Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Jianhua Guo
Mohamed Boudjelal
James W. Zapf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Incyte San Diego Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478342A1 publication Critical patent/CA2478342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002478342A 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases Abandoned CA2478342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36270202P 2002-03-08 2002-03-08
US60/362,702 2002-03-08
PCT/US2003/006784 WO2003075924A1 (en) 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases

Publications (1)

Publication Number Publication Date
CA2478342A1 true CA2478342A1 (en) 2003-09-18

Family

ID=27805215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478342A Abandoned CA2478342A1 (en) 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases

Country Status (14)

Country Link
US (2) US7102000B2 (https=)
EP (1) EP1487443A4 (https=)
JP (1) JP2005530705A (https=)
KR (1) KR20050006126A (https=)
CN (1) CN1649586A (https=)
AU (1) AU2003225682A1 (https=)
CA (1) CA2478342A1 (https=)
IL (1) IL163952A0 (https=)
MX (1) MXPA04008733A (https=)
NO (1) NO20044250L (https=)
RU (1) RU2004129752A (https=)
TW (1) TW200306184A (https=)
WO (1) WO2003075924A1 (https=)
ZA (1) ZA200408057B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
IL157740A0 (en) * 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) * 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CN1774246A (zh) * 2003-04-18 2006-05-17 因齐特圣迭戈公司 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ATE464564T1 (de) * 2004-08-30 2010-04-15 Takeda Pharmaceutical Screening-verfahren
US7638533B2 (en) 2005-09-30 2009-12-29 Janssen Pharmaceutica N.V. Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
US10449254B2 (en) * 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
EP3467459B1 (en) * 2016-06-07 2020-11-25 Mitsubishi Electric Corporation Temperature estimation method
JP7179354B2 (ja) 2016-08-29 2022-11-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚処置のためのイオン種に基づく局所処方物
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
ATE173728T1 (de) 1991-07-22 1998-12-15 Pfizer Verfahren zur herstellung von (s)-4-(3-(5-methyl- 2-phenyl-4-oxazolyl)- 1-hydroxypropyl> brombenzol
DE10199033I2 (de) 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
JPH08506323A (ja) 1992-11-25 1996-07-09 ラ ホヤ キャンサー リサーチ ファウンデーション Ｒｘｒホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
AU692839B2 (en) 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
EP0850067A4 (en) 1995-07-17 1999-12-15 Cird Galderma METHODS OF TREATING CANCER USING 6- 3- 1-ADAMANTYL] -4-HYDROXYPHENYL]
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
EP0844997A1 (en) 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
IL127946A0 (en) 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
WO1999009965A2 (en) 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000032598A1 (en) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
KR100608416B1 (ko) 1999-11-12 2006-08-02 후지모토 쿄다이 가부시키가이샤 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
EP1373240B1 (en) 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2003016267A1 (en) 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US20050014767A1 (en) 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
CN1774246A (zh) 2003-04-18 2006-05-17 因齐特圣迭戈公司 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物

Also Published As

Publication number Publication date
EP1487443A1 (en) 2004-12-22
CN1649586A (zh) 2005-08-03
IL163952A0 (en) 2005-12-18
JP2005530705A (ja) 2005-10-13
RU2004129752A (ru) 2005-05-10
KR20050006126A (ko) 2005-01-15
US20030216432A1 (en) 2003-11-20
MXPA04008733A (es) 2006-07-03
AU2003225682A2 (en) 2003-09-22
TW200306184A (en) 2003-11-16
NO20044250L (no) 2004-11-03
US20060241138A1 (en) 2006-10-26
WO2003075924A1 (en) 2003-09-18
US7102000B2 (en) 2006-09-05
AU2003225682A1 (en) 2003-09-22
ZA200408057B (en) 2007-05-30
EP1487443A4 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
US6765013B2 (en) Thiazolidinedione derivatives for the treatment of diabetes and other diseases
CA2478342A1 (en) Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20040034004A1 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
US20030144329A1 (en) N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US20050038098A1 (en) Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
EP1593677A2 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
HK1047591B (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes

Legal Events

Date Code Title Description
FZDE Discontinued